抗生素治疗对肌层浸润性膀胱癌新辅助帕博利珠单抗疗效的潜在不良影响
本研究基于PURE-01研究,评估合并使用抗生素(ATB)及特定类别ATB对新辅助帕博利珠单抗治疗的临床T2-4N0M0膀胱癌患者病理完全缓解(ypT0N0)和无复发生存(RFS)的影响。149例患者中48例(32%)接受ATB,ATB组ypT0N0率为15% vs 未使用组50%(p<0.001),ATB使用与ypT0N0负相关(OR 0.18,95%CI 0.05-0.48;p=0.001),24个月RFS率63% vs 90%,复发风险更高(HR 2.64,95%CI 1.08-6.50;p=0.03)。
要点
- 合并抗生素使用与更低的ypT0N0率和更差的RFS相关
- 氟喹诺酮类使用与更高复发率相关(HR 3.28)
- 需未来研究进一步验证该关联
核心结论
- 在意图治愈人群中,抗生素使用与新辅助免疫治疗疗效呈负相关。
研究设计与样本
- 基于PURE-01研究,评估149例临床T2-4N0M0膀胱癌患者接受新辅助帕博利珠单抗治疗。
主要发现
- 149例中48例(32%)接受任何合并ATB治疗,最常用为氟喹诺酮类(16例;33%)。
- ATB组7例(15%)达到ypT0N0,未使用组50例(50%;p<0.001)。
- ATB使用与ypT0N0负相关(OR 0.18,95%CI 0.05-0.48;p=0.001)。
- 24个月RFS率ATB组63%(95%CI 48-83%)vs 未使用组90%(95%CI 83-97)。
- ATB使用与更高复发率相关(HR 2.64,95%CI 1.08-6.50;p=0.03);氟喹诺酮类HR 3.28(95%CI 1.12-9.60;p=0.03)。
临床怎么用
- 在接受新辅助帕博利珠单抗的肌层浸润性膀胱癌患者中,应关注合并抗生素使用对疗效的潜在负面影响。
局限性
- 探索性分析结果需未来研究进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In locally advanced and metastatic malignancies, antibiotic (ATB) therapy has a negative effect on immunotherapy efficacy. Therefore, we aimed to evaluate whether ATB therapy and use of specific ATB classes with concomitant neoadjuvant pembrolizumab affected pathologic complete response (ypT0N0) and relapse-free survival (RFS) for patients with clinical T2-4N0M0 bladder cancer enrolled in the PURE-01 study. Of the 149 patients evaluated, 48 (32%) received any concomitant ATB therapy. The ATB class most commonly administered was fluoroquinolones (16 patients; 33%). In the ATB cohort, seven patients (15%) achieved ypT0N0 status, compared to 50 (50%; p < 0.001) in the untreated group. Moreover, ATB use was negatively associated with ypT0N0 status (odds ratio 0.18, 95% confidence interval [CI] 0.05-0.48; p = 0.001). The 24-mo RFS rate was 63% (95% CI 48-83%) in the ATB group versus 90% (95% CI 83-97) in the untreated group. We found that ATB use was associated with a higher recurrence rate (hazard ratio [HR] 2.64, 95% CI 1.08-6.50; p = 0.03). Exploratory analyses showed that fluoroquinolone use was associated with a higher recurrence rate (HR 3.28, 95% CI 1.12-9.60; p = 0.03). Our study revealed an association between ATB use and neoadjuvant immunotherapy efficacy in an intention-to-cure population, highlighting the need for future studies to better investigate this relationship. PATIENT SUMMARY: The efficacy of immunotherapy for cancer is influenced by several patient and tumor factors, including the use of antibiotics. We found that antibiotics taken at the same time as immunotherapy drugs were associated with lower rates of complete response and of recurrence-free survival among patients with muscle-invasive bladder cancer. These findings need to be confirmed in future studies.
引用
- Pederzoli F, Bandini M, Raggi D, et al. Is There a Detrimental Effect of Antibiotic Therapy in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Pembrolizumab? Eur Urol. 2021. PMID: 34053782. doi:10.1016/j.eururo.2021.05.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。